Kite, Alpine partner in immuno-oncology

Alpine Immune Sciences Inc. (Seattle, Wash.) granted Kite Pharma Inc. (NASDAQ:KITE) an exclusive, worldwide license to develop and commercialize chimeric antigen receptor (CAR) and T cell receptor ( TCR) therapies against two undisclosed cancer targets using Alpine's transmembrane immunomodulatory protein (TIP) platform.

Alpine will receive $5 million up front and is eligible for $530 million in research, clinical and regulatory milestones, plus low single-digit royalties. ...